Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
SAN DIEGO—Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), recently sold a total of 4,000 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The transactions took place over two days, with sales occurring on January 27 and 28. The biotech company, currently valued at approximately $980 million, has seen its stock surge nearly 10% over the past week.
The shares were sold at an average price range between $11.18 and $11.51, totaling approximately $45,380. According to InvestingPro analysis, the stock is currently trading above its Fair Value. Following the transactions, Ma Songjiang, through indirect ownership by a spouse, holds 2,895,138 shares. These sales were part of a pre-established Rule 10b5-1 trading plan adopted on September 13, 2024. InvestingPro data shows the company maintains strong liquidity with a current ratio of 3.72, indicating robust financial health. Subscribers can access 7 additional ProTips and comprehensive financial metrics for deeper analysis.
In other recent news, Gyre Therapeutics announced major changes in its leadership, with the appointment of Ping Zhang as the lead independent director of its Board of Directors. Zhang, who holds a prominent financial background, will also serve on the Nominating and Corporate Governance Committee. Simultaneously, Gyre Pharmaceuticals, a subsidiary of Gyre Therapeutics, reported Ying Luo’s resignation as Chairman, with Songjiang Ma taking over the role.
Zhang’s vast experience includes his present role as a Managing Partner at String Capital Management, and past roles at AEON Life Insurance (NSE:LIFI) Company and Japan Asia Investment Co. His academic credentials include a B.S. from Fudan University and an M.B.A. from the University of Chicago Booth School of Business.
These are recent developments that also involve the company’s focus on the development and commercialization of its drug F351 (Hydronidone) for MASH-associated fibrosis. Its subsidiary, Gyre Pharmaceuticals, is advancing its pipeline in the People’s Republic of China, including ongoing clinical trials for F351. The company reported total revenues of $105.03 million in the last twelve months, with an impressive gross profit margin of 96.23%.
Furthermore, Gyre Pharmaceuticals is also developing treatments for several other conditions, including COPD, PAH, and ALF/ACLF. The company anticipates a transformative year ahead, as stated by Han Ying, CEO of Gyre Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.